Principal Consultant
Payal Rabde – Senior Research Analyst
Payal Rabde is a Senior Research Analyst with over 4 years of experience in healthcare and life sciences market research, strategic analysis, and business intelligence. As a consultant to Precedence Research, she contributes to market assessment, forecasting, competitive intelligence, and commercial evaluation.
She is primarily associated with Towards Healthcare Research & Consulting, specializing in pharmaceuticals, biotechnology, diagnostics, medical devices, digital health, CRO/CDMO, cell and gene therapy, and healthcare IT.
Educational Background: MBA in Pharma-Biotech and Bachelor of Pharmacy (B.Pharm).
Core Expertise: Market sizing and forecasting, competitive intelligence, market opportunity assessment, commercial due diligence, pricing analysis, epidemiology-based market modeling, and go-to-market strategy.
Payal combines her pharmaceutical knowledge with analytical research capabilities to deliver meaningful market intelligence, identify emerging opportunities, and support informed business decisions across the healthcare and life sciences industries.
LinkedIn: Payal Rabde
No Media Citations Found.
The pathogen detection diagnostics market is forecasted to expand from USD 21.60 billion in 2026 to USD 35.86 billion by 2035, growing at a CAGR of 5.20% from 2026 to 2035.
The procalcitonin testing market is forecasted to expand from USD 352.59 million in 2026 to USD 664.76 million by 2035, expanding at a CAGR of 7.30% from 2026 to 2035.
The primary care POC diagnostics market is forecasted to expand from USD 20.38 billion in 2026 to USD 29.01 billion by 2035, growing at a CAGR of 4% from 2026 to 2035.
The metabolic testing market is forecasted to expand from USD 734.26 million in 2026 to USD 1,419.59 million by 2035, growing at a CAGR of 7.60% from 2026 to 2035.
The PARP inhibitor biomarkers market is forecasted to expand from USD 1.16 billion in 2026 to USD 2.56 billion by 2035, growing at a CAGR of 9.20% from 2026 to 2035.
The genetic disease diagnostic market is forecasted to expand from USD 12.62 billion in 2026 to USD 40.62 billion by 2035, growing at a CAGR of 12.40% from 2026 to 2035.
The gene panel market is forecasted to expand from USD 3.96 billion in 2026 to USD 13.68 billion by 2035, growing at a CAGR of 13.20% from 2026 to 2035.
The gastrointestinal diagnostics market is forecasted to expand from USD 6.44 billion in 2026 to USD 10.16 billion by 2035, growing at a CAGR of 5.20% from 2026 to 2035.
The fertility test market is forecasted to expand from USD 690.24 million in 2026 to USD 1,146.49 million by 2035, growing at a CAGR of 5.80% from 2026 to 2035.
The clostridium diagnostics market is forecasted to expand from USD 4.38 billion in 2026 to USD 8.60 billion by 2035, growing at a CAGR of 7.80% from 2026 to 2035.
The clinical oncology NGS market is forecasted to expand from USD 997.75 million in 2026 to USD 3,621.37 million by 2035, growing at a CAGR of 15.40% from 2026 to 2035.
The chlamydia infection diagnostics market is forecasted to expand from USD 874.26 million in 2026 to USD 1,580.46 million by 2035, growing at a CAGR of 6.80% from 2026 to 2035.
The cervical cancer screening, diagnostics and pre-cancerous dysplasia lesion treatment market is forecasted to expand from USD 9.97 billion in 2026 to USD 17.57 billion by 2035, growing at a CAGR of 6.50% from 2026 to 2035.
The cancer tumor profiling market is forecasted to expand from USD 17.71 billion in 2026 to USD 48.33 billion by 2035, growing at a CAGR of 11.80% from 2026 to 2035.
The brain cancer diagnostics market is forecasted to expand from USD 4.12 billion in 2026 to USD 6.51 billion by 2035, growing at a CAGR of 5.20% from 2026 to 2035.
The Europe recombinant protein manufacturing services market is estimated at USD 1,896.21 million in 2026 and is projected to reach USD 6,117.86 million by 2035, expanding at a CAGR of 13.9% from 2026 to 2035. The market was valued at USD 1,664.80 million in 2025, the base yearand it covers contract development and manufacturing of recombinant proteins, including antibodies, enzymes, hormones, cytokines, vaccine antigens and other therapeutic and research proteins, using mammalian, microbial, yeast and insect expression systems.
Market Size & Growth Outlook
The Europe equine healthcare market is estimated at USD 1,289.20 million in 2027. The market is projected to reach USD 2,555.72 million by 2036 with a growing CAGR of 7.90% from 2027 to 2036.
The global amniotic membrane market was valued at USD 5.35 billion in 2026 and is projected to reach USD XX billion by 2036, with an impressive CAGR of 13.35%. This growth is supported by rising demand for amniotic membrane in the ophthalmology sector and a surge in its usage in advanced wound care.
The Europe veterinary pharmaceuticals market is forecasted to expand from USD 9.52 billion in 2027 to USD 23.11 billion by 2036, growing at a CAGR of 10.35% from 2027 to 2036.
The global urology supplements market size is forecasted to expand from USD 2.43 billion in 2027 to USD 5.14 billion by 2036, growing at a CAGR of 8.65% from 2027 to 2036.
The global home blood pressure monitoring devices market is forecasted to expand from USD 1.71 billion in 2027 to USD 4.21 billion by 2036, growing at a CAGR of 10.5% from 2027 to 2036.
The blockbuster oncology brands market is forecasted to expand from USD 55.16 billion in 2027 to USD 110.83 billion by 2036, growing at a CAGR of 8.06% from 2027 to 2036.
The global massage equipment market is forecasted to expand from USD 13.27 billion in 2026 to USD 33.41 billion by 2035, growing at a CAGR of 10.80% from 2026 to 2035.
The aromatherapy diffusers market is forecasted to expand from USD 2.48 billion in 2026 to USD 5.23 billion by 2035, growing at a CAGR of 8.65% from 2026 to 2035.
The HbA1c testing devices market is forecasted to expand from USD 1.82 billion in 2026 to USD 4.30 billion by 2035, growing at a CAGR of 10.06% from 2026 to 2035.
The inhaled drugs contract manufacturing market is forecasted to expand from USD 4.30 billion in 2026 to USD 8.62 billion by 2035, growing at a CAGR of 8.04% from 2026 to 2035.
The pneumatic nebulizers market is forecasted to expand from USD 858.18 million in 2026 to USD 1517.72 million by 2035, growing at a CAGR of 6.54% from 2026 to 2035.
The global wound dressing market is forecasted to expand from USD 17.76 billion in 2026 to USD 26.05 billion by 2035, growing at a CAGR of 4.35% from 2026 to 2035.
The U.S. ambulatory surgery center market is forecasted to expand from USD 49.19 billion in 2026 to USD 84.17 billion by 2035, growing at a CAGR of 6.15% from 2026 to 2035.
The molecular nucleic acid testing transfusion medicine market is forecasted to expand from USD 1,053.61 million in 2026 to USD 1,710.27 million by 2035, growing at a CAGR of 5.53% from 2026 to 2035.
The cold and flu supplements market is forecasted to expand from USD 24.65 billion in 2026 to USD 68.51 billion by 2035, growing at a CAGR of 12.03% from 2026 to 2035.
The competent cells market is forecasted to expand from USD 3.55 billion in 2026 to USD 9.13 billion by 2035, growing at a CAGR of 11.05% from 2026 to 2035.
The North America allergy diagnostics market is forecasted to expand from USD 2 billion in 2026 to USD 5.12 billion by 2035, growing at a CAGR of 11.03% from 2026 to 2035. The United States represents the largest national market, supported by established healthcare infrastructure, specialist practices, and laboratory testing capabilities, while Canada and Mexico offer additional growth opportunities through improved diagnostic access and laboratory modernization.
The North America cardiovascular and soft tissue repair patches market is forecasted to expand from USD 2.81 billion in 2026 to USD 5.74 billion by 2035, growing at a CAGR of 8.25% from 2026 to 2035.
The North America enzyme replacement therapy market is forecasted to expand from USD 4.82 billion in 2026 to USD 10.23 billion by 2035, growing at a CAGR of 8.73% from 2026 to 2035.
The North America phenylketonuria treatment market is forecasted to expand from USD 436.00 million in 2026 to USD 946.95 million by 2035, growing at a CAGR of 9% from 2026 to 2035.
The rapid STI testing market is forecasted to expand from USD 1.74 billion in 2026 to USD 3.75 billion by 2035, growing at a CAGR of 8.9% from 2026 to 2035.
The DNA methylation market is forecasted to expand from USD 1.29 billion in 2026 to USD 4.54 billion by 2035, growing at a CAGR of 15.03% from 2026 to 2035.
The dental microscope market is forecasted to expand from USD 344.23 million in 2026 to USD 909.52 million by 2035, growing at a CAGR of 11.4% from 2026 to 2035.
The North America bioprocess analyzers market is forecasted to expand from USD 1.17 billion in 2026 to USD 3.38 billion by 2035 growing at a CAGR of 12.5% from 2026 to 2035. The market is driven by rising production of biologics and heavy investments in research and development.
The radiopharmaceutical preclinical CRO market is forecasted to expand from USD 2.50 billion in 2026 to USD 5.22 billion by 2035, growing at a CAGR of 8.55% from 2026 to 2035.
The North America nucleic acid amplification testing market is forecasted to expand from USD 4.91 billion in 2026 to USD 10.65 billion by 2035, growing at a CAGR of 9% from 2026 to 2035.
The North America cardiovascular repair and reconstruction devices market is forecasted to expand from USD 2.02 billion in 2026 to USD 3.50 billion by 2035, growing at a CAGR of 6.3% from 2026 to 2035. The market is driven by well-established reimbursement frameworks and supportive regulatory pathways from the U.S. FDA, along with substantial healthcare spending, funding fast market access and high-tech adoption.
The North America multi-modality aesthetic platforms market is forecasted to expand from USD 235.10 million in 2026 to USD 525.56 million by 2035, growing at a CAGR of 9.35% from 2026 to 2035.
The North America hereditary testing market is expected to grow at a CAGR of 15.02% during the forecast period, reaching USD 24.23 billion in 2035. The development of whole-genome sequencing and whole-exome sequencing approaches, growing awareness about the influence of genes, rapid advancement in infrastructure in developing markets, and the modernizing distribution environment are benefiting the market. Deepa Pandey, our Senior Research Analyst, has over 5 years of experience in the healthcare and medicine industry. According to her, the development of novel non-invasive sample collection approaches and the transition from target panels to whole-genome analysis are improving patient convenience and facilitating comprehensive genomic analysis, respectively.
Healthcare systems are becoming more structured and personalized in the treatment of bladder control disorders across Europe. Traditional urinary incontinence therapeutics are moving into the spotlight. Urinary incontinence is associated with diminished quality of life. There is an ever-increasing need for therapeutic options that will help this population achieve better outcomes, especially in aging. Deepa Pandey brings over 5 years of experience in market analysis in healthcare and life science. She notes a transformational shift in the urology care landscape in Europe, where patient awareness and the innovation of pharmaceutical play a key role in shaping practice patterns.
The surging respiratory and gastrointestinal infection cases have increased the need for rapid multi-pathogen testing from a single sample and reduced diagnostic turnaround times in critical care. Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. The market is estimated at USD 94.39 million in 2026, expanding at a CAGR of 5.95% during the forecast period from 2026 to 2035. The market is driven by expanding private and public healthcare diagnostic investments, adoption of cartridge-based point-of-care testing platforms, and major global assay launches entering the Indian market.
The computerized physician order entry market is forecasted to expand from USD 2.39 billion in 2026 to USD 4.16 billion by 2035, growing at a CAGR of 6.35% from 2026 to 2035. Thus, eliminating the manual ordering process. Deepa Pandey has more than 5 years of healthcare & life sciences market analysis experience. She observes a massive transformation in the field of healthcare digitization. CPOE systems enable physicians to electronically enter clinical orders such as medication, laboratory, imaging, and other orders, and link these orders with EHRs and clinical decision-support systems. On the other hand, Asia-Pacific is regaining its momentum in connection with the digitalization of hospitals and also the increasing investments in healthcare information systems.